Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CX 717

Drug Profile

CX 717

Alternative Names: Ampakine® CX717; CX717

Latest Information Update: 30 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer Cortex Pharmaceuticals; National Institute on Drug Abuse; RespireRx Pharmaceuticals
  • Class Antidementias; Nootropics; Small molecules
  • Mechanism of Action AMPA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder; Respiratory insufficiency
  • Phase I Spinal cord injuries
  • Preclinical Substance-related disorders
  • Discontinued Alzheimer's disease; Sleep disorders

Most Recent Events

  • 30 Jan 2019 CX 717 is still in phase II clinical trials for Respiratory insufficiency in Europe (PO)
  • 30 Jan 2019 RespireRx plans to file an IND, and initiate a phase IIb trial investigating the ability of CX 717 to improve breathing in patients with spinal cord injury, during 2018
  • 08 Jan 2018 RespireRx Pharmaceuticals plans further development of CX 717 in Attention deficit hyperactivity disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top